JACOBIO PHARMACEUTICALS GROUP CO., LTD. (JACOBIO-B) disclosed a next-day return detailing the on-market repurchase of 67,500 ordinary shares on 4 May 2026. Key figures from the filing are as follows:

• Transaction details: The shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 7.79 to HKD 7.84 per share, for a total consideration of HKD 0.46 million. The volume-weighted average cost was approximately HKD 6.82 per share as reflected in the filing.

• Impact on share capital: The buyback reduced the company’s outstanding share count (excluding treasury shares) from 785.21 million to 785.14 million, a marginal decline of 0.0086%. Concurrently, treasury shares rose from 6.55 million to 6.61 million, while total issued shares remained unchanged at 791.76 million.

• Repurchase mandate utilisation: Since receiving shareholder authorisation on 10 June 2025 to repurchase up to 78.87 million shares, JACOBIO-B has repurchased 3.59 million shares, representing 0.46% of the company’s issued share base on the mandate date.

• Post-repurchase restrictions: In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 3 June 2026.

No shares repurchased to date have been cancelled; all 67,500 shares acquired on 4 May 2026 are held as treasury stock.